A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

Upon confirmation of eligibility, participants were randomized in a 22:5:22:5 ratio to the following treatment groups: * Romosozumab 90 mg/mL * Placebo 90 mg/mL * Romosozumab 70 mg/mL * Placebo 70 mg/mL After completing a 6-month treatment period, participants entered a 3-month follow-up period with an end of study (EOS) at month 9. For the analysis of efficacy endpoints, the 2 placebo groups were combined into a single placebo group. For safety analyses, the data for placebo were presented separately for each group.